The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).
 
Sumit Kumar Subudhi
Stock and Other Ownership Interests - Apricity Health
Honoraria - Amgen; Apricity Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Dava Oncology; Dendreon; Exelixis; Janssen; Parker Institute for Cancer Immunotherapy; Polaris; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Amgen; Apricity Health; AstraZeneca; Bayer; Bristol-Myers Squibb; Dava Oncology; Dendreon; Janssen; Polaris; Valeant/Dendreon
Research Funding - AstraZeneca; Bristol-Myers Squibb; Janssen
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Compugen; Dava Oncology; Dendreon; Janssen; Parker Institute for Cancer Immunotherapy; Society for Immunotherapy of Cancer
 
Bilal A. Siddiqui
No Relationships to Disclose
 
Joseph J. Maly
No Relationships to Disclose
 
Lakshminarayanan Nandagopal
No Relationships to Disclose
 
Elaine Tat Lam
Consulting or Advisory Role - Calithera Biosciences
Research Funding - Advaxis (Inst); Amgen (Inst); Argos Therapeutics (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Immunomedics (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Decibel Therapeutics
 
Young E. Whang
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Regeneron (Inst)
 
Mukul Minocha
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Vinita Gupta
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Xianne Penny
No Relationships to Disclose
 
Freda Cooner
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Camila Jhones
No Relationships to Disclose
 
Andrew Paluch
No Relationships to Disclose
 
Mark Salvati
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Margit Janat-Amsbury
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Tobias Eggert
Employment - Amgen
 
Hosein Kouros-Mehr
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Anthony M. Joshua
Consulting or Advisory Role - AstraZeneca (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex